Abstract LB169: Establishment of patient-derived organoid (PDO) from single cell-originated core-needle biopsied (CNB) samples of breast cancer

Breast cancer (BC) exhibits differential subtypes with morphological and genetic heterogeneity. Lack of adequate ex vivo model and relevant PDO bank limits following clinical and applications and anti-cancer developments. Three-dimensional cell cultures, such as tumor spheroids, offered a promising alternative tool to reduce animal testing and act as patient avatar for cancer research. However, current platforms, such as scaffold-free low-adherence attachment plates, face challenges with low efficiency of spheroid formation and suffocate in handling rare cell samples. To address this issue, we employed the R3CE platform (Rapid, Reproducible, Rare Cell 3D Expansion; AcroCyte Therapeutics) to facilitate PDO cultivation and establishment including CNB samples based on single cell-derived 3D culture. Paired total 23 normal, 22 tumor, and 14 lymph node CNB tissue samples from various subtypes of cancer patients were collected for PDO culture. Observations revealed varied morphologies in paired normal versus tumor PDOs after culture. The overall successful rate was 84% (93% exclude lymph node) with normal PDO achieving 100% (23/23) success and tumor PDO culture reaches 86% (19/22) successful rate. Lymph node cultures on PDO had a success rate of 57% (8/14) due to potential sentinel node evaluation during routine examination. The established PDOs were confirmed by IHC staining for ER, PR, or Her2 expression. The tumorigenicity of the tumor PDOs was also validated through in vivo xenograft formation with pathology verified histological appearance. Our results demonstrate a streamlined procedures on amplification and establishment, enhancing PDOs model development and further clinical applications. Citation Format: Wen-Hung Kuo, Jia-Yang Chen, Chia-Chun Liu, Mark D. Pegram, Yu-Min Lin, Chia-Yuan Chang, Ying-Chih Chang. Establishment of patient-derived organoid (PDO) from single cell-originated core-needle biopsied (CNB) samples of breast cancer [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2025; Part 2 (Late-Breaking, Clinical Trial, and Invited s); 2025 Apr 25-30; Chicago, IL. Philadelphia (PA): AACR; Cancer Res 2025;85(8_Suppl_2): nr LB169.